You are here
FDA Approves Generic Alternative to Macrobid
Nitrofurantoin Monohydrate/Macrocrystals Capsules are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus.
"We are delighted to receive approval from the U.S. FDA to market this product to add to our every growing generic product portfolio. Our plans are to bring this product to the market as quickly as possible during the month of April," according to Jim Meehan, Vice President of Sales and Marketing for RPI.
Source: Ranbaxy Pharmaceuticals, Inc.